Cell Based Tech Weekly – Temasek Life Sciences Teams with Louis Dreyfus Company, Impossible Seeks New Capital

Temasek Life Sciences Accelerator (TLA) and Louis Dreyfus Company (LDC) announced a partnership through which Louis Dreyfus will “gain access to new or potentially disruptive technology under the Temasek Life Sciences accelerator’s portfolio.” – Temasek Life Sciences Program Manager, Cheryl Chng, informed me via email.

“TLA and LDC will be looking to invest in agri-tech projects of mutual interest, including but not restricted to biotechnologies for use in innovative food, feed and nutrition applications, and those which could improve agricultural productivity, food safety and traceability along the supply chain,” wrote Chng. 

Why We Care: Louis Dreyfus Company, a leading global agricultural commodities processor since 1851 is positioning itself at the forefront of innovation and disruption in agriculture by leveraging TLA’s expertise in life sciences research. Earlier this year, LDC invested in Motif Food Works further signaling, LDC recognition of a changing agricultural landscape to more biotech based solutions. https://cellbased.link/91a98 

Investments

With a current valuation of $2 billion after Impossible Foods most recent funding round, the plant based meat machine is now seeking more capital to the tune of $300-$400 million, according to Reuters article.  

With an aim to bolster up the company valuation to between $3 – $5 billion, Impossible is inching closer to rival, Beyond Meat, currently valued at $4.8 billion.